Surgalign Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Terry M. Rich
- Full Time Employees
- 217
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 520 Lake Cook Road Deerfield IL United States of America 60015
- IPO Date
- Aug 11, 2000
- CIK
- 0001760173
- Website
- surgalign.com
- Similar Companies
- Business
- Surgalign Holdings, Inc. engages primarily in the design, manufacture, and commercialization of innovative spinal implant and surgical technologies. Its core product portfolio includes spinal implants such as interbody fusion devices, posterior fixation systems, and bone graft substitutes; surgical instruments; regenerative orthobiologics; and robotics-assisted surgical technologies. Surgalign provides these products and services to hospitals, surgeons, and healthcare providers mainly across North America, with additional operations in select global markets. Founded in 2005 and headquartered in Houston, Texas, the company focuses on enabling minimally invasive and advanced spine surgery solutions. In recent developments, Surgalign has expanded its technology offerings and market reach through strategic partnerships and product launches within the last two years. The company has introduced new robotic-assisted surgery systems and enhanced its orthobiologics portfolio to improve surgical outcomes. Surgalign has also pursued acquisitions to broaden its footprint in the spine technology market and reinforced its commitment to innovation in spinal care. These operational and technological advancements reflect Surgealign's strategic efforts to consolidate its position as a comprehensive provider of spinal solutions. Surgalign operates in the medical device industry, specifically within the spinal surgery segment, targeting orthopedic and neurosurgical specialists. Its business segmentation spans implantable devices, surgical tools, biologics, and digital surgical assistive technologies. Surgalign holds proprietary technologies and maintains regulatory clearances to market its products internationally, supported by a network of subsidiaries and distribution partners. The company is publicly traded under the ticker symbol SRGA.
Why Is Surgalign Holdings (SRGA) Stock Up 10% Today?
Why Is Surgalign Holdings (SRGA) Stock Down 23% Today?
Why Is Surgalign (SRGA) Stock Down 55% Today?
Surgalign (SRGA) Upgraded to Buy: What Does It Mean for the Stock?
Surgalign Holdings, Inc. (SRGA) Q1 2023 Earnings Call Transcript
Surgalign Holdings (SRGA) Reports Q1 Loss, Tops Revenue Estimates
Surgalign Schedules First Quarter 2023 Earnings Release for May 11, 2023
Surgalign Holdings, Inc. (SRGA) Q4 2022 Earnings Call Transcript
Surgalign Schedules Fourth Quarter and Full Year 2022 Earnings Release for March 30, 2023
Surgalign Holdings, Inc. (SRGA) Q3 2022 Earnings Call Transcript
Surgalign Schedules Third Quarter 2022 Earnings Release for November 2, 2022
Surgalign Holdings, Inc. (SRGA) CEO Terry Rich on Q2 2022 Results - Earnings Call Transcript
Here's Why Surgalign Holdings Shares Are Falling Today
Surgalign Holdings' (SRGA) CEO Terry Rich on Q1 2022 Results - Earnings Call Transcript
Surgalign Holdings, Inc. (SRGA) CEO Terry Rich on Q4 2021 Results - Earnings Call Transcript
Surgalign Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release for March 15, 2022
Surgalign Shares Tank After $20 Equity Capital Raise
6 of the Best Penny Stocks Under $1 to Buy Now for 2022
Surgalign Holdings - A Future Of Digital Surgery
Surgalign Holdings, Inc. to Present at the 2022 H.C. Wainwright Virtual BioConnect Conference